JTK-853
- Generic Name
- JTK-853
- Drug Type
- Small Molecule
- Chemical Formula
- C28H23F7N6O4S2
- CAS Number
- 954389-09-4
- Unique Ingredient Identifier
- WDX8QQD13B
- Background
JTK-853 has been used in trials studying the treatment of Hepatitis C Virus Infection, Response to Therapy of.
Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT01475981
- Locations
- 🇺🇸
PPD, Phase I Clinic, Austin, Texas, United States
Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01473069
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects
Phase 1
Completed
- Conditions
- Hepatitis C Virus Infection, Response to Therapy of
- Interventions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01473056
- Locations
- 🇵🇷
Fundacion de Investigacion de Diego, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath